Log in

NYSE:COGlobal Cord Blood Stock Price, Forecast & News

0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $2.99
50-Day Range
MA: $2.89
52-Week Range
Now: $2.99
Volume646,317 shs
Average Volume286,523 shs
Market Capitalization$363.43 million
P/E Ratio5.44
Dividend YieldN/A
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).
Read More
Global Cord Blood logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars

Industry, Sector and Symbol

Industry Holding & other investment offices



Sales & Book Value

Annual Sales$172.50 million
Cash Flow$0.42 per share
Book Value$4.52 per share


Net Income$66.48 million


Market Cap$363.43 million
Next Earnings Date8/25/2020 (Estimated)

Receive CO News and Ratings via Email

Sign-up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter.

Global Cord Blood (NYSE:CO) Frequently Asked Questions

How has Global Cord Blood's stock been impacted by COVID-19 (Coronavirus)?

Global Cord Blood's stock was trading at $4.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CO stock has decreased by 26.5% and is now trading at $2.99. View which stocks have been most impacted by Coronavirus.

When is Global Cord Blood's next earnings date?

Global Cord Blood is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Global Cord Blood.

How were Global Cord Blood's earnings last quarter?

Global Cord Blood Corp (NYSE:CO) released its earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. Global Cord Blood had a return on equity of 12.64% and a net margin of 38.57%. View Global Cord Blood's earnings history.

Has Global Cord Blood been receiving favorable news coverage?

News coverage about CO stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Global Cord Blood earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Global Cord Blood.

Are investors shorting Global Cord Blood?

Global Cord Blood saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 26,500 shares, a decrease of 30.6% from the June 15th total of 38,200 shares. Based on an average trading volume of 178,200 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company's shares are sold short. View Global Cord Blood's Current Options Chain.

Who are some of Global Cord Blood's key competitors?

What other stocks do shareholders of Global Cord Blood own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include AbbVie (ABBV), Fate Therapeutics (FATE), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Rite Aid (RAD), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), Galectin Therapeutics (GALT), Gilead Sciences (GILD) and Intel (INTC).

Who are Global Cord Blood's key executives?

Global Cord Blood's management team includes the following people:
  • Ms. Ting Zheng, Chairman, CEO & Interim CEO of Beijing Division (Age 47)
  • Mr. Albert Chen, CFO & Director (Age 43)
  • Ms. Xin Xu, Chief Technology Officer (Age 65)
  • Ms. Rui Arashiyama, Chief Exec. Officer of Guangdong Division & Zhejiang Division (Age 60)
  • Ms. Cathy Bai, VP of Corp. Fin.

What is Global Cord Blood's stock symbol?

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

How do I buy shares of Global Cord Blood?

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Cord Blood's stock price today?

One share of CO stock can currently be purchased for approximately $2.99.

How big of a company is Global Cord Blood?

Global Cord Blood has a market capitalization of $363.43 million and generates $172.50 million in revenue each year. Global Cord Blood employs 1,261 workers across the globe.

What is Global Cord Blood's official website?

The official website for Global Cord Blood is www.globalcordbloodcorp.com.

How can I contact Global Cord Blood?

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.